PNT

NASDAQ

POINT Biopharma Global Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2020

News25/Ratings12

POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer; and PNT-2004, a fibroblast activation protein-a targeted radioligand to treat solid tumors. POINT Biopharma Global Inc. is based in Indianapolis, Indiana.

Latest news

25 items

695dPR
Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
836dSEC
SEC Form 15-12G filed by POINT Biopharma Global Inc.
15-12G - POINT Biopharma Global Inc. (0001811764) (Filer)
841dSEC
SEC Form EFFECT filed by POINT Biopharma Global Inc.
EFFECT - POINT Biopharma Global Inc. (0001811764) (Filer)
841dSEC
SEC Form EFFECT filed by POINT Biopharma Global Inc.
EFFECT - POINT Biopharma Global Inc. (0001811764) (Filer)
848dINSIDER
SEC Form 4 filed by Goodman Jonathan R.
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
848dINSIDER
SEC Form 4 filed by Kelly Justyna
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
848dINSIDER
Mccann Joe A. closing all direct ownership in the company (SEC Form 4)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
848dINSIDER
SEC Form 4 filed by Jensen Jessica D.
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
848dINSIDER
Fleshner Neil E. closing all direct ownership in the company (SEC Form 4)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
848dINSIDER
Hogue Gerald L. closing all direct ownership in the company (SEC Form 4)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
848dINSIDER
Malik Rajesh closing all direct ownership in the company (SEC Form 4)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
848dINSIDER
Lubner David Charles returned 3,600 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
848dINSIDER
SEC Form 4 filed by Demers William L.
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
848dINSIDER
SEC Form 4 filed by Silber Allan C
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
848dINSIDER
Margolin Yael returned 1,710 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
848d13D/G
SEC Form SC 13D/A filed by POINT Biopharma Global Inc. (Amendment)
SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)
848dNEWS
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ:FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain. In September, Oppenheimer initiated coverage on Fusion Pharmaceuticals, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies. Most recently, Bristol Myers Squibb & Co (NYSE:BMY) has agreed to acquire RayzeBio Inc (NASDAQ:RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. On Wednesda
848dSEC
SEC Form POS AM filed by POINT Biopharma Global Inc.
POS AM - POINT Biopharma Global Inc. (0001811764) (Filer)
848dSEC
SEC Form POS AM filed by POINT Biopharma Global Inc.
POS AM - POINT Biopharma Global Inc. (0001811764) (Filer)
848dSEC
SEC Form S-8 POS filed by POINT Biopharma Global Inc.
S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)
848dSEC
SEC Form S-8 POS filed by POINT Biopharma Global Inc.
S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)
848dSEC
SEC Form S-8 POS filed by POINT Biopharma Global Inc.
S-8 POS - POINT Biopharma Global Inc. (0001811764) (Filer)
848dSEC
SEC Form 25-NSE filed by POINT Biopharma Global Inc.
25-NSE - POINT Biopharma Global Inc. (0001811764) (Subject)
848dSEC
POINT Biopharma Global Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits
8-K - POINT Biopharma Global Inc. (0001811764) (Filer)
848dPR
Lilly Completes Acquisition of POINT Biopharma
INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ:PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly. "We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we